Sign In
Buy SYBX
$1.20
+0.0500 (+4.35%)
At Close: Jul 31, 2026
Synlogic's (SYBX) Begins Phase I Study for PKU Treatment
12:26pm, Friday, 16'th Jul 2021
Synlogic (SYBX) initiates phase I study of SYNB1934, a synthetic biotic candidate to treat PKU. The drug is an evolved strain of SYNB1618, another PKU candidate currently undergoing phase II study.
Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU)
06:30am, Thursday, 15'th Jul 2021
CAMBRIDGE, Mass., July 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that i
Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease
07:30am, Thursday, 17'th Jun 2021
CAMBRIDGE, Mass., June 17, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today that it
CAMBRIDGE, Mass., June 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the d
Synlogic to Present at Upcoming Virtual Banking and Industry Conference
08:30am, Tuesday, 25'th May 2021
CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoi
Synlogic Presents Data at Digestive Disease Week (DDW) on a Novel Approach for the Treatment of Inflammatory Bowel Disease
01:58pm, Sunday, 23'rd May 2021
CAMBRIDGE, Mass., May 23, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on a
Synlogic, Inc. (SYBX) CEO Dr. Aoife Brennan on Q1 2021 Results - Earnings Call Transcript
01:02pm, Thursday, 13'th May 2021
Synlogic, Inc. (SYBX) CEO Dr. Aoife Brennan on Q1 2021 Results - Earnings Call Transcript
Synlogic Reports First Quarter Financial Results and Provides Business Update
06:30am, Thursday, 13'th May 2021
CAMBRIDGE, Mass., May 13, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financia
3 Penny Stocks That Wall Street Wants You To Buy Now
02:51pm, Wednesday, 21'st Apr 2021
Penny stocks are very risky, which is why they have such low prices. Many of the companies in this risky part of the market will go bankrupt.
7 Penny Stocks That May Not Be Penny Stocks For Long
02:39pm, Wednesday, 21'st Apr 2021
Many penny stocks are destined for bankruptcy, but there are some that will survive. Wall Street thinks these companies are undervalued.
Synlogic Announces Pricing of Public Offering of Common Stock
06:00am, Friday, 16'th Apr 2021
CAMBRIDGE, Mass., April 16, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing
Synlogic Announces Proposed Public Offering of Common Stock
04:02pm, Thursday, 15'th Apr 2021
CAMBRIDGE, Mass., April 15, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has
CAMBRIDGE, Mass., April 13, 2021 Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data from the Phase 1 s
Synlogic Presents Data from SYNB1891 Phase 1 Trial at American Association for Cancer Research (AACR) Annual Meeting
09:37am, Saturday, 10'th Apr 2021
CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data o
Synlogic to Present at Upcoming Virtual Banking and Industry Conferences
03:33pm, Thursday, 01'st Apr 2021
CAMBRIDGE, Mass., April 1, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Ao
